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Not Its Crowning Glory:
Obstacles for FDA in Regulating Ingested Dietary Supplements
Purporting to Prevent Hair Loss
Abstract: Preventing hair loss is big business in the United States, amounting to over one billion
dollars per year. While the industry is dominated by FDA-approved medications, like Propecia and
Rogaine and hair transplant surgeries, there are also a variety of herbal remedies on the market
with no proof of eﬀectiveness. These products are allowed to exist and to claim to regrow hair or
prevent future hair loss thanks to the provisions of the Dietary Supplement Health and Education
Act of 1994, or DSHEA. This article examines how DSHEA allows these products to remain on the
market, potentially defrauding millions of vulnerable Americans seeking to respond to baldness, and
oﬀers several possible solutions to the problem.
Patient: Doctor, doctor, can you give me something for my baldness?
Doctor: How about a few pounds of pig manure?
Patient: Will that cure my baldness?
Doctor: No, but with that on your head no one will come near enough to notice you’re bald.
–Old Joke
While jokes like this one are common, for the sixty million American men and women who experience
signiﬁcant hair loss, baldness is no laughing matter.1 By one estimate, thirty-ﬁve million men in America
1Nicholas Thompson, Hair Today, Gone Tomorrow, Boston Globe, Feb. 12, 2002, at C3.
2are going bald, and 90% of them say it bothers them.2 And, while typical male-pattern baldness is not
indicative of serious medical problems, recent clinical studies by the American Academy of Dermatology
have demonstrated a link between hair loss and depression and other mental health problems, noting that
despite half of American men experiencing substantial receding by the age of ﬁfty, “[t]here is very little social
acceptance of hair loss.”3
The prevalence of the problem, combined with people’s dismay at its aﬀecting them, means big business for
those purporting to have found a cure. In America, baldness prevention and cures, including prescription
drugs, over the counter [OTC] drugs, hair transplants, dietary and herbal supplements, and other remedies,
represent a $1 billion business.4 In 2003 alone, Americans spent $111 million on Propecia, the FDA-approved
prescription baldness drug from Merck, up 13% from the previous year, and nearly one third of a billion
dollars on hair transplant operations.5 Given these ﬁgures, it is understandable why major drug companies
are investing heavily in ﬁnding a baldness cure, and why many dermatologists are making a living doing only
hair transplant operations.6 It is also understandable why many other less reputable characters are trying
to make money oﬀ of desperate men and women willing to try anything to avoid losing their hair. Throw in
the Internet and its ability to reach embarrassed or shy consumers unwilling to discuss the issue with their
doctors, and there are enormous opportunities for con artists to capitalize on this market.7
2See Jean Patterson, Huge Changes in Hair Replacement; Exciting Advances Seen in the Next Decade, Orlando Sentinel,
Dec. 21, 2005, at D5.
3The American Academy of Dermatology, Unraveling the Mystery of Hair Loss: Dermatologists Can Help Provide Answers,
Mar. 23, 2003, para. 16, at http://www.aad.org/public/News/NewsReleases/Press+Release+Archives/Hair/McMichaelHairLoss.htm.
4See Thompson, supra note 1, at C3.
5Dan Hurley, Does He or Doesn’t He? It’s Harder to Tell, N.Y. Times, June 15, 2004, at F1.
6See Thompson, supra note 1. GlaxoSmithKline is investing in dutasteride, a sort of next generation Propecia which serves
to block additional hormones believed to cause hair loss.
7See, e.g., Nicholas P. Terry, Prescriptions sans Frontieres (or How I Stopped Worrying About Viagra on the Web but Grew
Concerned About the Future of Healthcare Delivery), 4 Yale J. Health Pol’y & Ethics 183, 227 (2004) (“For many lifestyle drugs,
stealth and anonymity may still be the predominant factors promoting online purchases.”).
3Although there are only two drugs approved by the Food and Drug Administration for preventing hair loss,
Minoxidil [available over the counter, and known most commonly by its trade name, Rogaine] and Finasteride
[a prescription drug more recognizable by its trade name, Propecia], the Internet landscape and drug store
shelves are overﬂowing with products making unsubstantiated claims to “regrow” hair. A single Google
search for the words “hair loss remedy” returns links to over one million results, many of which promise
amazing, and supposedly scientiﬁcally proven, results. One might think that, given the prevalence of these
products, FDA is unaware of the problem.
Quite the contrary is true. FDA has been attempting to regulate the hair loss industry since twenty-ﬁve
years ago, when they ﬁrst proposed a rule proclaiming all products for external use purporting to regrow hair
or prevent hair loss be considered new drugs requiring FDA approval and review for safety and eﬀectiveness.8
The rule became ﬁnal after a lengthy notice and comment period in 1990, codiﬁed at 21 C.F.R §310.527.9
Despite this rule, products designed for internal use, e.g. pills and other dietary supplements, proclaiming
miracle cures for hair loss abound, amounting to a signiﬁcant portion of this billion dollar per year business.
This paper addresses the question of why these products continue to ﬂourish on the Internet, in pharmacies,
and in health food stores across the United States. Part of the answer surely is that this issue must, and
perhaps rightfully so, be low on FDA’s list of priorities, given that the agency is fulﬁlling such a broad
mandate with very limited resources.10 After all, there are no known or suspected cases of people potentially
dying from using a hair loss remedy, as there were with ephedra.11 Nevertheless, people are defrauded on
8Hair Grower and Hair Loss Prevention Drug Products for Over-the-Counter Human Use, 45 Fed. Reg. 73955 (Nov. 7,
1980).
9Hair Grower and Hair Loss Prevention Drug Products for Over-the-Counter Human Use, 54 Fed. Reg. 28772 (July 7, 1989)
(to be codiﬁed at 21 C.F.R. pt. 310).
10See Sharon Smith Holston, Drug Development: Who Knows Where the Time Goes?, 52 Food Drug L.J. 197 (1997)
(noting, “As the FDA’s workload continues to grow, the agency has to ﬁnd ways of doing more with less, without lowering the
standards of its public health protection.”).
11Dan Hurley, As Ephedra Ban Nears, Race to Sell Last Supplies, N.Y. Times, April 11, 2004, at A23.
4a daily basis by a cavalcade of hucksters, medicine men, and snake oil (pill) salesmen trying to capitalize
on desperate customers, and FDA recognized this when it decided to regulate hair loss products as drugs.12
FDA has engaged in some limited enforcement of the regulation, sending out several warning letters to
companies making topical products in violation of the law. But, these actions confront only a tiny fraction
of the products on the market, and do not touch the burgeoning market for dietary supplements claiming to
stop hair loss.
One reason for this may be the Dietary Supplement Health and Education Act of 1994, or as it is more
commonly known, DSHEA.13 This statute severely limited FDA’s ability to regulate so-called dietary sup-
plements, and it allowed dietary supplement producers to make a host of claims about their supplements’
ability to aﬀect the structure and function of the body.14 Congress enacted the statute to assure the availabil-
ity of dietary supplements for those who choose to use them, and it is premised on the nutritional beneﬁts of
such supplements.15 While FDA still technically has the ability to initiate some enforcement actions against
dietary supplements, the area in which they can act has been heavily circumscribed. Two commentators
have claimed in a recent article that “FDA’s enforcement activities against dietary supplement companies
committing egregious violations of DSHEA have virtually been non-existent.”16 Hair loss supplements, de-
spite the FDA’s 1990 regulation, almost certainly come under the act. I argue that if this is the case, it is
a concrete example of how DSHEA frustrates FDA’s mission to ensure that all drugs are safe and eﬀective,
and allows for the defrauding of millions of vulnerable Americans.
12See 54 Fed. Reg. 28772, supra note 9, noting: “One comment said the proposal was long overdue and that purchasers of
these drugs are bilked of millions of dollars each year.”
13Pub. L. 103-417, 108 Stat. 4325 (1994).
14See Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government
Regulation Five Years After Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food Drug L.J. 567,
576 (1999).
15I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History and
Analysis 1 (1996).
16Pinco & Halpern supra note 14, at 579.
5I will begin by discussing the landscape of the hair loss remedy market and FDA’s involvement with it,
discussing approved hair loss drugs, and examining what is available on the Internet and in drug and health
food stores. Then, I will brieﬂy review the history and impact of DSHEA, focusing on how it speciﬁcally
aﬀects the hair loss industry, suggesting that the statute inhibits FDA’s ability to protect consumers from
rampant fraud. I will conclude by examining possible solutions.17 I will suggest that while DSHEA is an
obstacle to taking hair growth pills oﬀ of the market, FDA may still be able to do it, particularly if it enforces
its recent draft guidance regarding the types of claims these products can legally make on their labels. I will
also suggest that market speciﬁc exceptions to DSHEA might provide the proper balance between Congress’s
desire to ensure the availability of safe dietary supplements, and FDA’s statutory mission.
A Survey of the Hair Loss Industry
By nearly any measure, the $1 billion dollar a year industry in hair loss prevention in this country is
enormous, and certainly large enough to garner the attention of the FDA. Over sixty million Americans
experience signiﬁcant hair loss each year, and most of them, at some point, seek to do something about it.18
Surprisingly, among this population of hair loss suﬀerers are nearly thirty million women, most of whom
experience an overall thinning instead of the more familiar male-pattern baldness, and for whom the process
17It is worthwhile at this point to note some issues this paper will not be discussing, though they are relevant to potential reg-
ulation of the hair loss industry. First, I will not examine in detail the growing concern about sales of prescription drugs through
online pharmacies. Propecia appears, along with Viagra and other lifestyle drugs, on many websites oﬀering prescriptions and
drugs online for consumers embarrassed to talk with a doctor about such personal issues. For an excellent introduction to the
problem, see generally Terry, supra note 7.
Additionally, this essay will not focus on the thorny issues surrounding direct-to-consumer (DTC) advertising of prescription
drugs. Hair loss drugs have historically been at the center of this debate, as Upjohn’s Rogaine with Minoxidil was the subject
of one of the ﬁrst direct to consumer ads. Propecial has also been aggressively marketed, with FDA issuing a warning letter in
1998 to Merck for being more positive than warranted by the scientiﬁc evidence. For full explanation of these incidents, and
a broader examination of DTC advertising of prescription drugs, see generally Wayne L. Pines, A History and Perspective on
Direct-to-Consumer Promotion, 54 Food Drug L.J. 489 (1999).
18Larry Hanover, Hair replacement: what works, what doesn’t, FDA Consumer, April, 1997, at 7.
6is more socially damaging.19 The problem, of course, is nothing new, as humankind has been engaged in
an ancient losing battle with baldness. Egyptians’ remedy of choice was a mixture of fats from mountain
goats, lions, crocodiles, serpents, geese, and hippopotami.20 Cleopatra oﬀered a mixture partly composed of
burnt mice to remedy Julius Caesar’s balding pate, while a late 18th century American manufacturer hawked
cocaine as a hair growth product.21
Unfortunately, while we have made some advances, we have not come very far. Although scientiﬁc studies
have led to several promising prescription baldness drugs and improved hair transplantation procedures,
pharmacies, health food stores, and the Internet remain chock full of supposed miracle cures. In this section,
I will survey the hair loss product market, looking at both FDA-approved and unapproved remedies.
FDA has approved two prescription drugs to treat hair loss: minoxidil, more commonly known as Rogaine,
and ﬁnasteride, more commonly known as Propecia. While neither drug is ﬂawless, and neither drug can
restore a bald head to the fullness of a person’s youth, each has been shown to be somewhat eﬀective,
with Propecia actually helping ﬁve of six users.22 Both drugs came from unintended sources. Minoxidil
was originally developed as a drug to reduce high blood pressure, but patients taking the drug began to
grow hair, often in unintended places.23 The drug underwent a lengthy FDA approval process, and is now
approved for over the counter sale to both men and women.24 Even after all this time, however, no one is
19Various Treatments Available for Female Hair Loss, FDA Law Weekly, Nov. 18, 2004, at 20.
20See Hanover, supra note 18, at 7.
21See Thompson, supra note 1, at C3.
22Id.
23Id.
24Lisa Skolnik, As in Men, Hair Loss in Women is Hereditary, Chicago Tribune, Aug. 14, 2002, at C5.
7quite sure what makes Minoxidil regrow hair some users.25 Furthermore, it must be used twice a day, every
day, or all that has been gained will be lost, which can be an expensive proposition as a year’s supply of
Rogaine can cost upwards of $400.26
The science behind Propecia, the second, and only other, FDA approved hair loss drug, is a bit more deﬁnite.
In brief, our genes cause most hair loss, and the trait can come from either side of the family.27 Hereditary
hair loss is caused by the over-production of a hormone called dihydrotestosterone, or DHT, which causes
the hair follicle to shrink and eventually die.28 So, each individual hair eventually gets thinner and loses its
capacity to grow until the follicle dies entirely. Doctors ﬁrst realized this connection when they noticed that
eunuchs never went bald, and the notion behind Propecia is that if you can stop the body from producing
too much DHT, you can stop the hair loss process.29 And, Propecia works fairly well at this, stopping hair
loss in ﬁve out six patients, and apparently regrowing some hair in two out of every three users.30
Despite this signiﬁcant success, manipulating hormone production can be a messy business, and the drug is
not without its risks. Another study in the law of unintended consequences, Propecia is descended from a
prostate drug called Proscar, also made by Merck, which contains the same drug as Propecia, ﬁnasteride,
just ﬁve times stronger.31 Patients taking Proscar to reduce enlarged prostates seemed to grow hair. Merck
25Devera Pine, Hair! From Personal Statement to Personal Problem, F.D.A. Consumer, Dec. 1991, at 20.
26See Skolnik, supra note 24, at C5.
27American Academy of Dermatology, August is Hair Loss Awareness Month, July 28, 2003, at
http://www.aad.org/public/News/NewsReleases/Press+Release+Archives/Hair/AugustHairLossAwareness.htm.
28Id.
29See Thompson, supra note 1.
30Id.
31Richard L. Cupp, Jr., The Continuing Search for Proper Perspective: Whose Reasonableness Should Be at Issue in a
Prescription Product Design Defect Analysis?, 30 Seton Hall L. Rev. 233, 235 (1999).
8noticed the connection and developed a weaker version as a baldness remedy.32 However, Proscar carried
with it a signiﬁcant risk of side eﬀects, not all of which are eliminated by the smaller dose of ﬁnasteride
present in Propecia.33 In particular, Propecia can cause sexual side eﬀects, which range in intensity from
loss of libido to full-on impotence, in around two percent of users.34 Additionally, Propecia is of no help to
women, who cannot even touch the pills for fear of causing birth defects to a future child.35 Furthermore,
Propecia is not foolproof, and it is very expensive. A one year supply of Propecia can cost around $600,
cost prohibitive for many. And, Propecia only inhibits one of the two sources of DHT production in men,
but help may be on the way as GlaxoSmithKline is developing a drug called dutasteride that attacks both
sources of the hair-destroying hormone.36
For those for whom the drugs do not work, there remains a burgeoning industry in hair transplants. Con-
sumers spent nearly a third of a billion dollars in 2003 on hair transplant operations, which now cost on
average about $32,000 each.37 And, as transplants grow more realistic and less painful, that number will
surely rise, particularly if current research comes to fruition and doctors are eventually able to clone the
hair follicle. Current transplants require actually taking growing hair follicles from the back of the head
and transplanting them to bald areas. If cloning becomes feasible, doctors will be able to sprout an entire
head of hair from a single functioning follicle.38 For the more skittish, there remains a strong market in
wigs and toupees,39 and for those who don’t mind a continual battle with wind, there is always the Donald
32Id.
33Id.
34Robert Davis, Hair Raising Discoveries, Bald Gene Finding Could Add to Growing Options, USA Today, Feb. 3. 1998,
at 1D.
35Hair Growth Pill to Be Oﬀered Next Month, Chicago Sun-Times, Dec. 23, 1997, at 1.
36See Thompson, supra note 1.
37See Hurley, supra note 5, at F5.
38Id.
39Douglas Century, A Little Sympathy for the Toupee...er, Hair System, N.Y. Times, at Sec. 9, p. 4.
9Trump-esque combover hairdo.40
That, in a sense, is the good news. The bad news is that the market is also ﬁlled with products claiming
to regrow hair with no FDA approval whatsoever. A trip to my local drug store revealed an entire shelf-
section devoted to such products, from the FDA approved Minoxidil products to a series of pills claiming
to grow hair. My local Vitamin Shoppe is also well-stocked with herbs claiming to have a positive eﬀect
on hair growth, such as extract of Saw Palmetto berries and Shen Min. The Internet has exacerbated the
problem, as “natural” hair loss remedies are everywhere online, from the web to email, in the form of spam
advertisements. The slickness of these websites, complete with video, client testimonials, and before/after
pictures, makes the products appear to work extremely well, while any disclaimer that the products have
not been approved by the FDA are in very ﬁne print.41
FDA has been in the business of attempting to regulate the hair loss industry for the last twenty-ﬁve years.
In the November 7, 1980 Federal Register, FDA proposed a rule covering products claiming to prevent hair
loss or grow new hair.42 After a nearly decade-long comment period, the ﬁnal rule was announced on July
7, 1989, and would become eﬀective on January 8, 1990.43 The agency was concerned about products being
ineﬀective, and “consumers being bilked” into buying phony remedies.44 The ﬁnal rule states that “any
OTC drug product that is labeled, represented, or promoted for external use as a hair grower or for hair loss
prevention” be considered a new drug, and go through the new drug approval process.45 The FDA based
40See Rich McKay, Hair-raising Comb-over; Hairstyle Patent Proves Worthy of Ig Nobel Prize, Houston Chronicle, Oct. 13,
2004, at 2. The article notes that Harvard University awarded the inventors of the “comb-over” hairstyle an “Ig Nobel Prize”
at a 2004 banquet, earning a “trophy of an empty cereal box and a pie-plate medal hanging from a shoestring.”
41A good example of this is the website for “Hair Genesis,” available at http://www.hairgenesis.net, which includes all of
these features, and has such a disclaimer in almost unreadable ﬁne print at the very bottom of the homepage.
42“Hair Grower and Hair Loss Prevention Drug Products for Over-the-Counter Human Use,” 45 Fed. Reg. 73955, Nov. 7,
1980 (to be codiﬁed as 21 C.F.R. §310.527).
4354 Fed. Reg., supra note 9, at 28772.
44Id.
45Id. at 28777.
10this decision on a lack of evidence demonstrating that any product then on the market was eﬀective for hair
regrowth or hair loss prevention, stating that “[b]ased on evidence currently available, all labeling claims
for OTC hair grower and hair loss prevention drug products for external use are either false, misleading, or
unsupported by scientiﬁc data. Therefore, any OTC drug product for external use containing an ingredient
oﬀered for use as a hair grower or for hair loss prevention cannot be considered generally recognized as
safe and eﬀective for its intended use.”46 FDA has often enforced this regulation against shampoos, tonics,
or serums that claim to regrow hair, usually by sending a warning letter to producers whose products are
violation.47
The rule explicitly did not reach products intended to be ingested, although the FDA did comment on the
matter in response to a comment suggesting that the rule be extended to ingestible remedies.48 FDA stated
that products intended for internal use were explicitly outside the scope of the regulation, but that such
products might be regulable as new drugs if they make “drug claims.”49 This notion, however, predates the
Dietary Supplement Health and Education Act of 1994, which allows products labeled as dietary supplements
to make claims that they aﬀect the structure and function of the body without prior approval from the FDA.
And, predictably, these products are almost all labeled as dietary supplements.50 If DSHEA allows for these
products to make hair regrowth claims in the guise of a dietary supplement, then it makes s signiﬁcant
46Id.
47See, e.g. ,Letter from Michael A. Chappell, Director of the Dallas District of the Food and Drug Administration, to Rudolph
Johnson, Owner of Pride and Power, Inc. (Mar. 3, 2003), available at http://www.fda.gov/foi/warning letters/g3870d.htm.
The letter warns Mr. Johnson that his company’s product “Don’t-B-Bald Hair and Scalp Treatment Medicated” is in violation
of the regulation and faces further action if the problem is not rectiﬁed.
4854 Fed. Reg., supra note 9, at 28772.
49Id. at 28773.
50FDA has occasionally initiated actions against producers who make pill products and some drug claims when those products
are not labeled as dietary supplements. See Letter from Jerome G. Woyshner, Director of the New York District of the
Food and Drug Administration, to Anthony Imbriolo, President of Global Vision Products, Inc. (April 3, 2003), available at
http://www.fda.gov/foi/warning letters/g3938d.htm.
11dent in 21 C.F.R. §310.527, and shows the propensity for frauds to be perpetrated on the public thanks to
DSHEA.
Before turning to DSHEA’s speciﬁc provisions, I will review some of the claims made by hair loss products
labeled as dietary supplements. One popular product is called “NuHair,” and it is readily available in drug
stores and on the Internet.51 On its website, NuHair claims that it:
Integrates a revolutionary combination of Traditional Chinese Medicine with the applied science
of modern technology. The result is a nutriceutical anti-thinning tablet that provides intensive
nourishment for excessively thinning hair, receding hairlines, breakage around the hairline, and any
area of the scalp that has poor hair density. This natural nutrient booster supplies vital botanical
components to nourish the hair. NuHair supports embryotic follicular activity naturally to encourage
hair regrowth.52
It is clear that if NuHair were a topically applied product, it would come within the ambit of 21 C.F.R.
§310.527 because it claims to encourage regrowth of hair. However, because the product is a pill, and is
orally ingested, it does not fall under the regulation. Furthermore, the product box states in small let-
ters in the bottom left-hand corner “Dietary Supplement,” which brings it under the aegis of DSHEA.
NuHair is only one example of such products claiming to regrow hair which are labeled as dietary supple-
ments.53Theseproductsarenotregulableas“newdrugs,
00andpresentapotentialfraudperpetratedontheAmericanpublic.
51NuHair Homepage, available at http://www.nuhairproducts.com/nuhair/nuhair.htm.
53Other examples abound on the Internet and in health food stores. I will provide a few here:
• Hair Genesis Oral Soft-gels, available at http://www.hairgenesis.net. The website claims: Through 10 years of
on-going clinical research and product usage testing, these botanicals have been shown to interfere with key hormonal processes
implicated in the onset and progression of pattern hair loss in both men and women.
• New Generation 2 Dietary Supplement, available at http://www.newgen2000.com/treatment/dietary-supplement.html.
The website claims: The New Generation Nutritional Supplement is designed to provide the missing nutritional elements that
are known to have an eﬀect on hair health and a reduction in baldness.
• Natrecia, available at http://www.hairsite.com/secure/razack natrecia.htm. The website claims: Natrecia is a
completely natural, vitamin, mineral, and herbal supplement speciﬁcally developed for combating the eﬀects of androgenic
alopecia (AP) (i.e., male-pattern baldness). Its formulation is based on a signiﬁcant body of research that ﬁrmly establishes
the eﬀect that certain natural agents have in combating the eﬀects of dihydrotestosterone (DHT) in the treatment of benign
prostatic hyperplasia (BPH).
12How the Dietary Supplement Health and Education Act arguably creates cover for hair loss
remedies marketed as “dietary supplements”:
The Dietary Supplement Health and Education Act of 1994 fundamentally altered the FDA’s regulatory
relationship with the dietary supplement industry, and, therefore, the industry itself.54 DSHEA, which
signiﬁcantly limited FDA’s ability to regulate the dietary supplement industry, has ushered in enormous
growth in the use of these supplements.55 In fact, about sixty percent of Americans take some form of
dietary supplement, and sales of such products have nearly doubled since the passage of DSHEA.56 And
FDA’s ability to regulate this ever-growing market has been so circumscribed by the statute that, in some
circles, being “DSHEA’ed” is a code for deregulation.57
In this section, I will brieﬂy review the history of FDA’s regulation of dietary supplements, a history which
led directly to a grass roots movement resulting in the unanimous passage of DSHEA in the House and
Senate.58 Then, I will discuss how the statute limits FDA’s ability to regulate the dietary supplement
industry, particularly with respect to claims such supplements might make about health beneﬁts, such as
the ability to grow hair. The statute arguably allows myriad hair growth remedies labeled as supplements
to make unsubstantiated claims of eﬀectiveness, circumventing FDA’s explicit regulation of the industry in
54Sean Harmon, Melatonin Mania: Can the FDA Regulate Hormonal Dietary Supplements to Protect Consumer Interests
in Light of the Dietary Supplement Health and Education Act of 1994?, 22 Dayton L. Rev. 77, 86 (1996).
55Meghan Colloton, Dietary Supplements: A Challenge Facing the FDA in Mad Cow Disease Prevention, 51 Am. U. L.
Rev. 495, 496 (2002) (noting that “the use of dietary supplements has increased dramatically in the United States over the
last decade.”).
56Stephanie Kauﬂin, Dietary Supplements: Is Availability Worth the Risks? Proposed Alternatives to the Present DSHEA
Scheme, 33 Seton Hall L. Rev. 411, 413 (2003).
57Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of Choice,
49 Fla. L. Rev. 665, 666 (1997).
58Laura A. W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 54 Food Drug L.J. 623 (1999).
1321 C.F.R. §310.527. Finally, I will review FDA’s recent eﬀorts to increase regulation of dietary supplements
under DSHEA and discuss how these eﬀorts, if enforced, may ameliorate the situation.
1. The History of Dietary Supplement Regulation Before DSHEA
The FDA has been engaged in a battle with the dietary supplement industry over regulations for over sixty
years.59 While it is beyond the scope of this paper to review the entire history of FDA’s attempts to regulate
the supplement industry, a brief overview is necessary to understanding the climate surrounding the passage
of DSHEA, and its limitations of FDA’s power.
The FDA promulgated their ﬁrst regulations of dietary supplements in 1941, requiring minimum daily
requirements on labels for some supplements.60 These early regulations did not meet much resistance, but
they were not particularly onerous either. The real ﬁght began when FDA sought to revise these regulations
in 1962. The agency was concerned that supplements were spreading “myths of nutrition,” suggesting
that people could not receive necessary sustenance from a normal diet.61 The new proposals would set a
mandatory limit on the potency of a supplement at 150% of its recommended daily allowance.62 The new
regulations also prohibited inclusion of ingredients “not recognized by ‘competent authorities’ as essential or
as having signiﬁcant nutritive value to humans.”63 These regulations sparked a public and industry backlash
so enormous that the proposed rules not only were never promulgated, they never even made it to the public
59See Gilhooley, supra note 57, at 671.
60See Colloton, supra note 55, at 512.
61See Gilhooley, supra note 57, at 673.
62See Colloton, supra note 55, at 513.
63Id.
14hearing stage.64
FDA again attempted to pass similar rules in 1966, but public outcry was so great that the agency stayed
the regulations the day before they were to become eﬀective and launched a two-year public hearing phase.65
Particularly oﬀensive to the public and supplement manufacturers was FDA’s proposed requirement that
every dietary supplement label state that because the regular diet provided adequate nutrition, “there is
no scientiﬁc basis for recommending routine use of dietary supplements.”66 Eventually, FDA dropped this
requirement, but in 1973 it did issue a ﬁnal rule classifying most vitamins with a potency greater than 150%
of the recommended daily allowance as drugs, and prohibiting sales of supplements with combinations of
vitamins and minerals, with few exceptions.67
These regulations were supposed to take eﬀect in 1975, but due to an “overwhelming number of constituent
letters written to Congress,” nearly seventy bills were introduced to limit FDA’s ability to regulate potency
of dietary supplements.68 A three-year congressional debate ensued, with particularly virulent argument on
both sides. Senator William Proxmire led the charge for those attempting to thwart the new regulations. His
ﬂoor statement about the issue was particularly forceful: “What the FDA wants to do is strike the views of
its stable of orthodox nutritionists into ‘tablets,’ and bring them down from Mount Sinai where they will be
used to regulate the rights of millions of Americans, who believe they are getting a lousy diet, to take vitamins
64Bass & Young, supra note 15, at 11.
65Id.
66Colloton, supra note 55, at 514.
67Bass & Young, supra note 15, at 11.
68Colloton, supra note 55, at 516.
15and minerals. The real issue is whether the FDA is going to play ‘God.”’69 In the end, Proxmire prevailed,
and Congress passed an amendment to section 411 of the FDCA which, among other things, prohibited
FDA from setting potency limits on vitamins and minerals, and allowing those supplements to be sold in
various combinations.70 Not only did the Proxmire Amendment hinder FDA’s attempts to regulate the
dietary supplement industry, it also demonstrated both the enormous public resistance to such regulations,
and Congress’ willingness to respond with legislation.
FDA responded to the Proxmire amendment by scaling back its attempts to regulate the dietary supplement
industry, but the agency found creative ways to enter the fray if it felt there was a legitimate safety concern.71
FDA regulated some supplement ingredients as food additives, which require premarket approval if they are
not generally recognized as safe.72 The approval process for a new food additive is so ﬁnancially onerous and
takes so long that this was usually enough to remove the substance from the market.73 This approach was
reasonably eﬀective, but it required FDA to proceed on a case-by-case basis, rather than issuing a regulation
covering the entire market for dietary supplements.
In 1990, Congress passed the Nutrition Labeling and Enforcement Act (NLEA) which set standards for health
claims made by foods. The statute did not set such standards for dietary supplements, but directed FDA
to craft them.74 Although the drafters of the statute clearly intended for dietary supplements to face more
69Bass & Young, supra note 15, at 12 (quoting 121 Cong. Rec. 39979 (1975) (statement of Senator William Proxmire)).
70Colloton, supra note 55, at 517.
71Gilhooley, supra note 57, at 676.
72Colloton, supra note 55, at 518.
73Id. According to Colloton, the approval process for a food additive not generally recognized as safe can cost up to $2 million
and take up to six years.
74Id. at 520.
16lenient standards than food in general, FDA responded by applying the same strict guidelines which applied
to food to supplements.75 And, perhaps to underscore the strictness of the regulations, the only supplement
claim FDA deemed to possibly meet these standards was calcium’s ability to prevent osteoperosis.76
FDA’s action again sparked a backlash from the supplement industry and the public, and Congress quickly
enacted the Dietary Supplements Act of 1992, staying the eﬀect of FDA’s regulations under NLEA until
December 1993.77 In the interim, 38 people died and 1500 others experienced adverse health eﬀects from use
of L-tryptophan, an amino acid supplement used by bodybuilders.78 As a result, FDA again attempted to
issue broad regulations, in the form of an advance notice of rulemaking, of the supplement industry similar
in many ways to those it proposed in the 1960s.79 The proposed rules again sparked a backlash by consumers
and the industry, galvanizing support for legislation to reign in FDA.80 One colorful stunt by the industry
was a “National Blackout Day,” in which health food stores covered with black drapes the products that
would supposedly be aﬀected by FDA’s proposed rules. The stunt contributed to the growing outcry over
FDA’s proposed regulations, and eventually to the passage of DSHEA.81
2. The passage of DSHEA and its limitations on FDA’s ability to regulate dietary supplements.
In short, Congress responded to calls for greater access to dietary supplements by unanimously passing the
Dietary Supplement Health and Education Act of 1994, which was signed into law by President Clinton on
75Id. at 521.
76Bass & Young, supra note 15, at 15.
77Colloton, supra note 55, at 522.




17October 25, 1994.82 Congressman Bill Richardson called the bill’s passage “a great victory for the more
than 100 million Americans who use these products.”83 The bill, which is premised on “the role of nutrition
and beneﬁts of dietary supplements in health promotion,” ﬂatly contradicts the FDA’s eﬀorts to regulate
supplements more like drugs and less like foods.84 Yet, the act also clearly removes supplements from
regulation as food additives, which FDA had done in a reasonably successful, albeit piecemeal, fashion since
the 1970s.85 In all, as one article recently asserted, DSHEA “directly thwarted” FDA’s attempts to increase
restrictions on dietary supplements.86
DSHEA deﬁnes dietary supplements essentially as products containing vitamins, minerals, herbs, or other
botanicals, amino acids, or any other “dietary substance for use by man to supplement the diet by increasing
the total dietary intake,” including combinations of any of these ingredients.87 A dietary supplement must
also be intended for ingestion and labeled as a supplement.88 This redeﬁnition makes it clear that a dietary
supplement can be placed on the market without the preclearance that would be required of a new drug or
a food additive.89 This change constitutes a signiﬁcant liberalization of the law.
FDA still has the ability, in some circumstances, to take a supplement oﬀ of the market if it is dangerous,
and they can do so immediately if the product presents an imminent hazard to public health or safety.90
However, FDA has to overcome a major hurdle in order to get a supplement oﬀ of the market for being unsafe,
because the statute clariﬁes that the burden of proof is on the government to show that a supplement is
82Id. at 1260-61.
83Bass & Young, supra note 15, at 30.
84Id. at 1.
85Id. at 33. See also, 21 U.S.C.A. 321(s)(6).
86Harmon, supra note 54, at 78.
8721 U.S.C. §321(ﬀ).
88Id.
89Pinco & Halpern supra note 14, at 569.
9021 U.S.C. §342(f)(1)(C).
18adulterated.91 The result is that many of the avenues FDA once pursued in regulating dietary supplements,
for instance as a drug or food additive, have been explicitly eliminated.
Perhaps even more signiﬁcant to the issue of hair loss supplements, because such products are usually worth-
less but not dangerous, is DSHEA’s provision allowing supplements to make claims that they alter the
structure or function of the body (so-called structure function claims). Furthermore, supplement makers
may make these claims without premarket approval by FDA or treatment as a new drug.92 These provisions
represent the drafters’ intention to increase consumer access to accurate information regarding dietary sup-
plements.93 I will examine them here, and then explain how they allow market entry for hair loss remedies
which are useless.
DSHEA allows supplement makers to make “statements of nutritional support,” including descriptions of
“the role of a nutrient or dietary ingredient intended to aﬀect the structure or function in humans, or
general well-being from consumption of a nutrient or dietary ingredient.”94 However, the ability to make
such structure function claims is not completely unlimited. The claims must be substantiated, although
this term is not deﬁned, and the products’ labels must include a disclaimer explaining that the claims
have not been evaluated by the FDA, and that the product is not intended to prevent, treat, or cure any
disease.95 Additionally, the supplement maker must notify FDA within thirty days of when the product is
9121 U.S.C. §342(f)(1).
92Pinco & Halpern, supra note 14, at 569.
93Id.
9421 U.S.C. §343(r)(6). See also Gilhooley, supra note 57, at 684.
9521 U.S.C. §343(r)(6).
19ﬁrst marketed to notify them that the claim will be made.96 The most important thing about the statute
is that post-DSHEA dietary supplements can make these claims without premarket approval from FDA,
while over-the-counter drugs must go through the arduous preclearance process.97 It is the manufacturer’s
responsibility to ensure product labeling is truthful and not misleading.98
The result, naturally, has been an explosion of nutritional and structure functions claims on dietary sup-
plements, relating to a wide array of health problems, from insomnia to prostate health.99 The hair loss
industry has certainly not failed to take advantage of these new provisions. A cursory glance at products
available on the web and at pharmacies will see the tell tale signs of DSHEA-compliant labels—including
the words “dietary supplement” and the scripted FDA disclaimer. NuHair is not the only example of a
product that bills itself as a “hair regrowth tablet,” and gets away with it because it bills itself as a dietary
supplement.100 The “oral soft-gels” available as part of the aforementioned “Hair Genesis” system, which
claims on the same web-page that it is the “safest and most eﬀective hair loss treatment remedy available,”
and also that (in ﬁne print, of course) “the information provided on the website is intended for informational
purposes only,” and that the claims made on the website have not been evaluated by FDA.101
One reason for the explosion of health claims under DSHEA is a lack of deﬁnition in the statute for “substan-
tiation” required to make a health claim on a supplement label.102 As Pinco and Halpern state, “It is not
96Pinco & Halpern, supra note 14, at 576.
97Gilhooley supra note 57, at 685.
98Dietary Supplements Overview, Food and Drug Administration, Dec. 10, 2004, available at
http://www.cfsan.fda.gov/∼dms/supplmnt.html.
99Id.
100See NuHair Hair Regrowth Tablets for Men, supra note 52.
101Hair Genesis Overview, supra note 53
102Pinco & Halpern, supra note 14, at 576.
20entirely clear how much data a company needs in order to substantiate a structure/function statement.”103
Hair loss websites, like Hair Genesis, often oﬀer “clinical studies” to back up their claims of eﬀectiveness,
but since there are no clear standards deﬁning what sorts of studies actually substantiate these claims, such
studies must be taken with a grain of salt.104 Unfortunately, despite the required disclaimer that appears on
these products’ websites, they still have a veneer of scientiﬁc proof attached to them, usually “backed up”
by a series of user testimonials and photographs of questionable legitimacy.
FDA has recognized this problem, and has recently attempted to deﬁne the substantiation required by
DSHEA. Its actions may represent a fruitful avenue to reduce fraud in a way that is consistent with both
the language and the spirit of the statute.
3. FDA’s recent attempts to re-enter the fray in regulating dietary supplement structure function claims:
The exponential growth of the dietary supplement industry since the passage of DSHEA, and the concomitant
explosion of claims made on supplement labels, has prompted FDA to announce major new initiatives to
provide guidance to the dietary supplement industry on November 4, 2004.105 Among these initiatives
is a “draft guidance”106 attempting to deﬁne the level of substantiation necessary to make a structure
function claim while also maintaining “ﬂexibility in the precise amount and type of evidence that constitutes
adequate substantiation.”107 The press release announcing the initiative indicated FDA’s hope to coordinate
103Id.
104Hair Genesis Overview, supra note 53. The studies cited on this website claim to be, among other things, independently
veriﬁed, peer-reviewed, placebo-controlled, Institutional Review Board monitored, randomized, and double-blind.
105FDA Announces Major Initiatives for Dietary Supplements, Nov. 4, 2004, available at
http://www.fda.gov/bbs/topics/news/2004/NEW01130.html.
106Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food,
Drug, and Cosmetic Act, 69 Fed. Reg. 64962, (Nov. 9, 2004).
107Id.
21with FTC’s eﬀorts to stamp out fraud in dietary supplement labeling, and FTC Chairman Deborah Platt
Majoras added, “The guidance FDA has issued today sends a clear and strong reminder to marketers that
claims about the beneﬁts of dietary supplements, wherever they appear, must be truthful and substantiated
by high quality scientiﬁc evidence.”108
Obviously, the proposal is only a draft guidance, which means that the industry is not legally obligated
to follow it, and response may well be the type of signiﬁcant backlash from the supplement industry and
consumers that the FDA has faced over the last ﬁve decades, but if implemented, the draft guidance would
be a major step forward. In essence, the guidance attempts to provide a very general framework as to how
a structure function claim might be substantiated: “Although there is no formula as to how many or what
type of studies are needed to substantiate a claim, FDA intends to apply a standard of ‘competent and
reliable scientiﬁc evidence.”’109 While the guidelines do not get much more speciﬁc than that, FDA does
indicate that they will look at the meaning of the claim asserted, the relationship of the evidence to the
claim, the quality of that evidence, and the totality of the evidence to decide whether the claim has been
substantiated.110 The implication of this wide-ranging, case-by-case, method of analysis, is that FDA is
asserting its power to clarify the substantiation requirement in DSHEA to look more closely at structure
function claims made by dietary supplements. If enforced as written, the guidance represents a much more
active approach in regulating dietary supplement claims than previously practiced under DSHEA.
Possible Ways FDA Might Prevent So-Called Dietary Supplements from Claiming to Regrow
Hair
108Id.
109Fact Sheet on FDA’s Draft Guidance for Industry: Substantiation for Dietary Supplement Claims (hereinafter
known as Fact Sheet), Nov. 4, 2004, available at http://www.cfsan.fda.gov/∼dms/dsclmfs.html.
110Id.
22Dietary supplements purporting to regrow hair in balding men and women provide a textbook case of how
DSHEA allows products to make strong claims about how they impact the structure and function of the body
with little substantiation and no approval from the FDA. While these products do not appear to present
any immediate health risks to the general public, they do represent a possibility of fraud.111 And, there is
additional reason to be concerned because consumers losing their hair constitute a particularly vulnerable
population, seeking any solution to their impending baldness, particularly women.112 FDA should attempt
to ﬁnd ways consistent with DSHEA to keep products that provide false hope to balding men and women
oﬀ of the market.
One promising avenue is the new draft guidance for how FDA will enforce the requirement that dietary
supplement structure function claims be substantiated. Many of the products available on the web assert that
clinical studies support their claims to regrow lost hair, but these studies are of varying worth, and without
FDA oversight, consumers have no means of diﬀerentiating between them. Yet, FDA’s draft guidance oﬀers
an excellent opportunity for the agency to take some of these products oﬀ of the shelves without running afoul
of DSHEA. This is precisely because of the DSHEA’s mandate that the manufacturer have substantiation
that the claims are truthful and not misleading.113 By explicitly focusing on the relationship between the
speciﬁc claim to the evidence, the quality of that evidence, and the totality of the evidence supporting the
claim, FDA will be able to ensure that hair loss products do not overstate their eﬀectiveness or hide behind
bogus studies.114 Furthermore, the coordination of standards with the FTC could have the beneﬁts of both
111Indeed, there are not yet any known cases of a consumer dying from ingesting a hair loss supplement. However, some of
these supplements contain a signiﬁcant number of herbs. It is not unimaginable that one of these combinations could provoke an
adverse reaction in a user. For instance, the Natrecia product contains: Saw Palmetto Berries Extract 400 mg; Beta Sitosterol
200 mg; Rye Pollen Extract 100 mg; Pumpkin Seed Extract 100 mg; Lycopene 50 mg; Zinc 20 mg;Copper 1 mg; Vitamin B6
(pyridoxal-5-phosphate) 10 mg; Phosphorus (as phosphate) 100 mg; Calcium 125 mg. See Natrecia, supra note 53.
112See Eileen Dempsey, Heartache of Hair Loss, Columbus Dispatch, Mar 25, 2002, at 1C.
11321 U.S.C. §343(r)(6)(B).
114See Fact Sheet, supra note 109.
23reducing the FTC’s enforcement load and sending a consistent message to the supplement industry from the
federal government.115
The FDA, of course, may have to contend with the backlash which has always accompanied attempts to more
closely regulate the dietary supplement industry. It is certainly possible that perceived overreaching by FDA
in regulation of substance function claims will spark additional eﬀorts to persuade Congress to intercede, even
if the guidance complies fully with the language of §343(r)(6)(B). FDA so far has restricted action under the
new guidance to warning letters sent to manufacturers of weight loss products.116 If there is little backlash
to these actions, it would not be a signiﬁcant step further to start cracking down on products like Natrecia
or NuHair. But, if FDA begins to make attacks on other health claims made by supplements focused on
supplementing the diet or helping the heart, they may experience the sort of widespread discontent that has
accompanied their regulatory eﬀorts since the 1960s.
One could also make an argument that FDA could deal with these products as new drugs under DSHEA
even if they are labeled as dietary supplements. Even though 21 C.F.R. §310.527 is not written to apply
to internally ingested products, the accompanying comment and text of the regulation indicate that FDA
treats a claim by a product to regrow hair as a health claim. The ﬁnal text of the rule states that any
over the counter product for external use that claims to regrow hair must be treated as a new drug.117 It
is not a long leap to the conclusion that a claim by any product to regrow hair is a health claim which
115See FDA Announces Major Initiatives for Dietary Supplements, Nov. 4, 2004, available at
http://www.fda.gov/bbs/topics/news/2004/NEW01130.html.
116Id.
117See 54 Fed. Reg., supra note 9, at 28777.
24must be preapproved through the new drug process, especially when the accompanying comment to the ﬁnal
rule states that FDA retains the authority to take action against internally ingested products making these
claims.118 Furthermore, FDA has said in other materials that “claims such as restoration of hair growth,
hair loss prevention, and treatment of dandruﬀ” are classiﬁed as drugs and not cosmetics because of the
claims the products make.119
The key question is whether FDA could do this consistent with DSHEA, but they probably could if one
considers hair loss prevention or hair regrowth a health claim as opposed to a structure function claim.
Distinguishing structure function from health claims, however, is extremely tricky.120 A health claim, which
requires premarket approval before a product can assert it, is deﬁned as “any claim... that expressly or by
implication,... characterizes the relationship of any substance to a disease or health-related condition.”121
Given the previous characterizations of hair loss prevention claims as health claims requiring preapproval
in 21 C.F.R. §310.527, it would be diﬃcult for the industry to claim complete lack of notice were this
interpretation applied to ingested dietary supplements for hair loss. Characterizing these claims as health
claims rather than structure function claims would allow FDA to keep these products from making these
claims until there is “signiﬁcant scientiﬁc agreement” about them.122 One objection, of course, to this
approach is that it violates the spirit of DSHEA, which explicitly allows structure function claims to be
made on dietary supplement labels. FDA, however, might try this approach with respect to a fringe product
like hair loss remedies to test the level of backlash it might face from both Congress and the public.
118See 54 Fed. Reg., supra note 9, at 28772.
119See Warning Letters Address Hair Care Products, available at http://www.cfsan.fda.gov/∼dms/cos-hres.html.
120See Pinco & Halpern, supra note 14, at 577.
121See id. at 572, quoting 21 C.F.R. §101.14(a)(1).
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25One advantage of approaches targeting claims these products make, as opposed to taking them oﬀ the
market entirely, is that it ensures people the freedom to continue taking a safe, if ineﬀective, product if they
so choose. These approaches, therefore, takes steps toward preventing fraud while also avoiding being caught
on the horns of the argument Senator Proxmire expressed so vehemently in 1975.123 As such, if there are
true believers, or people who for whatever reason believe they are responding to a particular supplement,
they may continue to use the product if they so choose.
Finally, one other possible solution, if neither of these approaches work, is for Congress to make product-class
exceptions under DSHEA. Given the extensive support for the freedom to use dietary supplements in general
(remember, DSHEA passed the Senate and the House unanimously), any appearance that FDA is attempting
to extend its regulatory reach across the board might spark a response. This response, however, may be from
groups who fear that their vitamins and minerals might be taken away from them, and FDA might not be
as motivated to go after these products. One approach might be for FDA to highlight some particular types
of products which make uniformly unsupported claims while calling themselves dietary supplements—such
as hair loss or weight loss products. Congress might be more willing to carve out exceptions to DSHEA to
prevent consumer fraud for these sorts of questionable products, while still ensuring that consumers have
access to more traditional and germane nutritional supplements like Vitamin C, calcium, and the like.
This approach, however, would necessitate Congress re-entering the fray on an issue they may have considered
settled. Congress might also balk at setting a precedent that might encourage FDA to come calling every time
123See Bass & Young, supra note 15, at 12.
26it found a class of supplements it wanted to regulate—thus potentially posing a threat to those consumers
who have campaigned so vigorously in the past for their freedom of choice in taking supplements.
Conclusion
Given the vulnerability of consumers worried about losing their hair, it presents a signiﬁcant risk of fraud if
ingestible hair loss products are able to provide false hope through unproven claims. If DSHEA is interpreted
to allow these sorts of claims simply because a product bears the label dietary supplement, then the law
creates a license to commit fraud. However, there seem to be several opportunities available within the
statute for the FDA to reverse course if it chooses to act.
The new draft guidance explaining FDA’s point of view regarding the substantiation requirement for structure
function claims allowed under 21 U.S.C. §343(r)(6) provides an excellent framework for evaluating claims
on hair loss products, and eventually removing those that are unconﬁrmable, and perhaps leading to more
studies that will push us closer to a real remedy. In time, however, we will be able to see if FDA is able
to put real teeth in the requirement, and can enforce it without facing the signiﬁcant backlash that has
accompanied their past attempts to regulate the dietary supplement industry.
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